These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 25592727)
1. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? Bega D; Gonzalez-Latapi P; Zadikoff C; Spies W; Simuni T Neurodegener Dis; 2015; 15(2):81-6. PubMed ID: 25592727 [TBL] [Abstract][Full Text] [Related]
2. DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Yomtoob J; Koloms K; Bega D Parkinsonism Relat Disord; 2018 Aug; 53():37-41. PubMed ID: 29748111 [TBL] [Abstract][Full Text] [Related]
3. Impact of DAT-SPECT on Management of Patients Suspected of Parkinsonism. Mirpour S; Turkbey EB; Marashdeh W; El Khouli R; Subramaniam RM Clin Nucl Med; 2018 Oct; 43(10):710-714. PubMed ID: 30153144 [TBL] [Abstract][Full Text] [Related]
4. The role of DAT-SPECT in movement disorders. Kägi G; Bhatia KP; Tolosa E J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):5-12. PubMed ID: 20019219 [TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Ba F; Martin WR Parkinsonism Relat Disord; 2015 Feb; 21(2):87-94. PubMed ID: 25487733 [TBL] [Abstract][Full Text] [Related]
6. Experience with DaTscan at a tertiary referral center. Sadasivan S; Friedman JH Parkinsonism Relat Disord; 2015 Jan; 21(1):42-5. PubMed ID: 25465746 [TBL] [Abstract][Full Text] [Related]
7. Referral practice, reporting standards, and the impact of dopamine transporter scans done in a tertiary hospital. Bhattacharjee S; Chalissery AJ; Barry T; O'Sullivan D; O'Connell M; Lynch T Neurol India; 2017; 65(6):1264-1270. PubMed ID: 29133699 [TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study. Tsang K; Walker R J Neurol; 2023 May; 270(5):2550-2558. PubMed ID: 36795149 [TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center. Graebner AK; Tarsy D; Shih LC; Vanderhorst V; Kulkarni O; Kaplan S; Simon DK Neurodegener Dis; 2017; 17(1):38-43. PubMed ID: 27614874 [TBL] [Abstract][Full Text] [Related]
10. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. Subramaniam RM; Frey KA; Hunt CH; Mercier GA; Solnes LB; Colletti PM; Lu Y; Savir-Baruch B; Williams HT Clin Nucl Med; 2017 Nov; 42(11):847-852. PubMed ID: 28922189 [TBL] [Abstract][Full Text] [Related]
11. How can neuroimaging help in the diagnosis of movement disorders? Ling H; Lees AJ Neuroimaging Clin N Am; 2010 Feb; 20(1):111-23. PubMed ID: 19959023 [TBL] [Abstract][Full Text] [Related]
12. Clinical routine use of dopamine transporter imaging in 516 consecutive patients. Thiriez C; Itti E; Fénelon G; Evangelista E; Meignan M; Cesaro P; Remy P J Neurol; 2015; 262(4):909-15. PubMed ID: 25649832 [TBL] [Abstract][Full Text] [Related]
13. The predictive value of transcranial sonography in clinically diagnosed patients with early stage Parkinson's disease: comparison with DAT PET scans. Liu P; Li X; Li FF; Ou-Yang QH; Zhang HX; Feng T Neurosci Lett; 2014 Oct; 582():99-103. PubMed ID: 25218716 [TBL] [Abstract][Full Text] [Related]
14. [Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders]. Kanyó B; Argyelán M; Dibó G; Szakonyi Z; Vécsei L; Fülöp F; Láncz A; Forgács P; Pávics L Ideggyogy Sz; 2003 Jul; 56(7-8):231-40. PubMed ID: 12971118 [TBL] [Abstract][Full Text] [Related]
15. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Scherfler C; Schwarz J; Antonini A; Grosset D; Valldeoriola F; Marek K; Oertel W; Tolosa E; Lees AJ; Poewe W Mov Disord; 2007 Jul; 22(9):1229-38. PubMed ID: 17486648 [TBL] [Abstract][Full Text] [Related]
16. Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center. Oravivattanakul S; Benchaya L; Wu G; Ahmed A; Itin I; Cooper S; Gostkowski M; Rudolph J; Appleby K; Sweeney P; Fernandez HH Mov Disord Clin Pract; 2016; 3(1):31-35. PubMed ID: 30363515 [TBL] [Abstract][Full Text] [Related]
17. [Functional neuroimaging in movement disorders]. Borbély K Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452 [TBL] [Abstract][Full Text] [Related]
18. [Utility of dopamine transporter imaging (123-I Ioflupane SPECT) in the assessment of movement disorders]. García Vicente AM; Vaamonde Cano J; Poblete García VM; Rodado Marina S; Cortés Romera M; Ruiz Solís S; Ibáñez Alonso R; Soriano Castrejón A Rev Esp Med Nucl; 2004; 23(4):245-52. PubMed ID: 15207208 [TBL] [Abstract][Full Text] [Related]